Vertex Pharma's New Drug Submission for Cystic Fibrosis Treatment Accepted for Review in Canada
Express News | Vertex Announces Health Canada Acceptance of New Drug Submission for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-in-Class Triple Combination Treatment for Cystic Fibrosis
Vertex Pharmaceuticals Presents Vanzacaftor/tezacaftor/deutivacaftor Data
Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA at the North American Cystic Fibrosis Conference
Pfizer Withdraws Sickle Cell Drug Oxbryta Over Safety Concerns
Vertex Receives Health Canada Marketing Authorization for Sickle Cell Disease Treatment
Express News | Health Canada Grants Marketing Authorization of First CRISPR/Cas9 Gene-Edited Therapy, Casgevy® (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,200 Today
Vertex Pharmaceuticals (VRTX) Stock Declines While Market Improves: Some Information for Investors
The Best Biotech Plays Outside the GLP-1 Weight-loss Market
Express News | RBC Capital Reiterates Sector Perform on Vertex Pharmaceuticals, Maintains $431 Price Target
Vertex Pharmaceuticals Analyst Ratings
Vertex Pharmaceuticals (VRTX) Gets a Hold From RBC Capital
Gene Editing Therapeutics Market Report 2024, Featuring Profiles of Key Players Allogene Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, Sangamo Therapeutics and Vertex Pharmaceuticals - ResearchAndMarkets.com
What Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) P/S Is Not Telling You
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years
Vertex Pharmaceuticals, Inc. (VRTX) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
'Trump Trade' vs. 'Harris Trade': How They Could Shape Your Portfolio
Vertex Pharmaceuticals Incorporated (VRTX) Is Attracting Investor Attention: Here Is What You Should Know
Is Vertex Pharmaceuticals Stock Outperforming the Nasdaq?